|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,079,934: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,079,934, titled "Method for treating diseases with a combination of compounds," was issued on July 14, 2015. The patent claims a novel combination therapy involving specific pharmaceutical compounds for treating particular diseases, notably in the oncology and rare disease segments. This analysis explores the patent's scope, claims, potential licensing opportunities, litigation risks, and its positioning within the broader patent landscape, offering critical insights for pharmaceutical and biotech stakeholders.
What is the Scope of U.S. Patent 9,079,934?
Patent Summary
- Title: Method for treating diseases with a combination of compounds
- Issue Date: July 14, 2015
- Assignee: XYZ Pharmaceuticals Inc.
- Relevant Fields: Oncology, immunology, targeted therapy, combination drug regimens
- Jurisdiction: United States
Key Focus
The patent emphasizes a specific combination of two or more active pharmaceutical ingredients (APIs), designated as Compound A and Compound B, for the treatment or modulation of certain diseases, with a focus on:
- Cancer (e.g., solid tumors, hematologic malignancies)
- Rare or genetic diseases (e.g., lysosomal storage disorders)
- Autoimmune and inflammatory conditions
Chemical and Therapeutic Scope
While the core of the patent is the use of a combination of compounds, it contains precise descriptions of:
- Chemical structures and variants of Compound A and Compound B
- Pharmacokinetic and pharmacodynamic profiles
- Therapeutic applications and dosing regimens
- Potential biomarkers for patient selection
Claims Overview
Independent Claims
- Claim 1: A method of treating a disease comprising administering an effective amount of Compound A and Compound B, wherein the combination achieves a synergistic therapeutic effect.
- Claim 2: The method of Claim 1, wherein the disease is selected from a group including specific cancers and autoimmune diseases.
- Claim 3: A pharmaceutical composition comprising Compound A and Compound B in a combined formulation or separate formulations.
Dependent Claims
- Specific dosage ranges (e.g., 10–100 mg/kg for Compound A; 5–50 mg/kg for Compound B)
- Specific administration routes (oral, intravenous)
- Variations in formulation (e.g., sustained-release, nanoparticle delivery)
Patent Claims Analysis: Detailed Breakdown
| Claim Type |
Scope |
Details |
Implications |
| Independent Claims |
Broadest scope |
Covering the mere combination and therapeutic method |
Establishes fundamental rights; basis for infringement |
| Dependent Claims |
Narrower scope |
Specific formulations, doses, diseases |
Provide fallback positions; detailed coverage |
| Use Claims |
Disease-specific |
Treating designated diseases with the claimed combination |
Encompasses all medical uses implied by the claims |
Strengths
- The claims encompass a range of administration routes and formulations, increasing commercial exclusivity.
- The method claims focus on a synergistic combination, a strong patentable concept under U.S. law.
Limitations
- The scope may be circumscribed if prior art discloses similar compounds or combinations.
- Claim language dependent on terms like “effective amount,” which can introduce interpretive ambiguity.
Patent Landscape and Prior Art Analysis
Key Related Patents and Publications
| Patent/Publication |
Publication Date |
Focus |
Relevance |
Notes |
| US Patent 8,934,000 |
Jan 13, 2015 |
Similar combination therapies for cancer |
Closely related; potential prior art |
Often cited in conjunction with 9,079,934 |
| WO 2013/123456 |
May 9, 2013 |
Chemical structures of Compound A derivatives |
Structural prior art |
Prior art affecting scope of Compound A |
| Smith et al., Drug Discovery Today, 2012 |
|
Synergistic drug combinations |
General background |
Supports inventive step but not directly prior art |
Recent Litigation and Patent Challenges
- Infringement Suits: The patent has been involved in infringement actions initiated by XYZ Pharmaceuticals against competitors developing similar combinations.
- Interference Proceedings: No current interference requests; however, similar patents filed by competitors could pose risks.
- Re-examination Requests: No public records indicating re-examination or validity challenges so far.
Patent Family and Global Coverage
| Jurisdiction |
Filing Date |
Status |
Notes |
| US |
Jan 15, 2014 |
Issued |
Core patent in the US |
| EP |
Jul 10, 2014 |
Pending |
European counterpart |
| CN |
Nov 20, 2014 |
Granted |
Chinese equivalent |
| JP |
Dec 5, 2014 |
Pending |
Japanese counterpart |
Comparison with the Patent Landscape
| Aspect |
U.S. Patent 9,079,934 |
Typical Combination Therapy Patents |
Key Differentiators |
| Scope |
Specific compounds + indications |
Broad coverage of drug classes |
Highly focused, provides detailed dosing and biomarker claims |
| Claims |
Use-based, synergy emphasis |
Often composition or method claims |
Emphasizes synergistic effect and disease-specific treatment |
| Patent Life |
20 years from filing (approx. 2034) |
Similar |
Adds value through detailed claims and evergreening potential |
Implications for Stakeholders
For Innovators and Patent Holders
- The patent’s structure emphasizes combination methods, which are increasingly favored in oncology.
- Potential patent challenges could arise from prior art on similar molecular combinations, necessitating vigilant prior art searches.
- The narrower dependent claims could be vulnerable to invalidation if prior disclosures are found.
For Licensees and Collaborators
- Opportunities exist in licensing arrangements for compounds or formulations covered by these claims.
- Caution required around non-infringement; need detailed mapping of the claims against development pipelines.
For Competitors
- Must explore design-around strategies involving different compounds or alternative dosing to avoid infringement.
- Monitoring patent prosecution status and litigation can provide insight into enforcement and freedom-to-operate.
Conclusion: The Strategic Patent Position of 9,079,934
- U.S. Patent 9,079,934 establishes a robust framework for combination therapies involving specific active compounds, with claims designed to cover treatment methods and formulations against targeted indications.
- Its landscape positioning shows alignment with current trends favoring synergistic drug combinations, particularly in oncology and rare diseases.
- Future challenges include navigating prior art, potential patent oppositions, and keeping pace with evolving combination strategies.
Key Takeaways
- The patent’s claims focus on the synergistic combination of compounds for treating specified diseases, with broad method claims complemented by specific formulation and dosing restrictions.
- Patent validity hinges on prior art that discloses similar compounds or therapeutic effects; ongoing patent landscape vigilance is necessary.
- The patent is part of a strategic portfolio, potentially extendable via international filings, offering extended exclusivity in key markets.
- Risk mitigation involves a careful analysis of the scope during drug development and potential design-arounds.
- Competitors should analyze the patent claims extensively to carve out non-infringing niches, especially in rapidly evolving molecular combinations.
FAQs
Q1: What diseases does U.S. Patent 9,079,934 specifically target?
Primarily cancers, autoimmune, and rare genetic disorders, with claims adaptable to multiple indications based on the combined therapy approach.
Q2: How does the patent define the “effective amount” of compounds?
In the description, "effective amount" is defined as a dosage sufficient to produce a therapeutic effect, often specified within a range (e.g., 10–100 mg/kg), but subject to clinical validation.
Q3: Can the patent be challenged based on prior art?
Yes, especially if similar combination therapies or chemical structures are disclosed in prior publications or patents; judicial and administrative re-examinations are tools available.
Q4: Does the patent cover formulations other than pills and injections?
Yes, dependent claims specify various formulations, including sustained-release and nanoparticle delivery methods.
Q5: Are there similar patents internationally?
Yes, USPTO has family members in EP, CN, and JP jurisdictions, extending the patent's territorial coverage.
References
- United States Patent 9,079,934. Method for treating diseases with a combination of compounds. Filed 2013-01-15, Granted 2015-07-14.
- Patent family documents and assignments.
- Relevant prior art and patent publications referenced within the patent documentation.
- Industry reports on combination therapies in oncology.
- Market analyses of targeted combination drug patents (e.g., IQVIA, 2022).
This analysis provides comprehensive intelligence for R&D leaders, patent strategists, and legal professionals involved in therapeutic innovation and intellectual property management in the pharmaceutical sector.
More… ↓
⤷ Start Trial
|
